AU · rank #2 · 2026-10-21
ATEC
NASDAQ · $1.68B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.857 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.00 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $1,013,150 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $15.79 | +51.6% |
| Momentum acceleration 3-month minus 12-month momentum. | +35.01% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.79 |
| Gross margin TTM | +70.8% |
| 52w high | $23.29 |
| Market cap (USD) | $1.68B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Alphatec Holdings develops and commercializes integrated spinal surgery solutions, including implants, access systems, SafeOp neuromonitoring, EOS full-body imaging, and the Valence navigation and robotics platform.
Rationale
The ~51.6% analyst upside signal is supported by strong operational momentum, including 20% surgical case-volume growth, 24% net-new surgeon growth, and an upwardly revised 2026 adjusted EBITDA target of $140 million.
Material risks
- 1Well-capitalized competitors like Medtronic, Globus Medical, and Stryker could leverage broader product suites and enterprise hospital contracting to displace ATEC's EOS Insight and Valence platforms.
- 2A heavy debt burden of ~$510.7 million relative to ~$119 million in cash leaves the balance sheet vulnerable if surgical revenue growth or free-cash-flow conversion decelerates.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.